Floatz logo

Acetylcysteine

Schizophreniform Disorder

University of Maryland, BaltimoreSmall moleculePhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Schizophreniform Disorder cohort.

Asset / SponsorPhaseRating
Olanzapine
Alkermes, Inc.
Phase 4A
Raloxifene
Iris Sommer
Phase 4A
Dexmedetomidine
BioXcel Therapeutics Inc
Phase 4A
Risperidone
Northwell Health
Phase 4BBB
SIMVASTATIN
Iris Sommer
Phase 3BB

View all 39 →

Same molecule, other indications

Acetylcysteine is also rated in:

idiopathic pulmonary fibrosisActive
BBB
Indicative · Phase 4
74 / 100
View asset →
pulmonary fibrosisActive
BB
Indicative · Phase 3
70 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative · Phase 2
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →